A Selective M1 and M3 Receptor Antagonist, Penehyclidine Hydrochloride, Exerts Antidepressant-Like Effect in Mice
- 14 Downloads
Recent studies indicate that anti-muscarinic receptor is a prospective strategy to treat depression. Although non-selective antagonist of muscarinic receptor scopolamine exhibits rapid and robust antidepressant-like effect, it still has various side effects including abuse risk. Penehyclidine hydrochloride (PHC) is a novel clinical anti-cholinergic drug derived from scopolamine in China, which selectively blocks M1 and M3 muscarinic receptor. Therefore, the objective of this study was to evaluate whether PHC would manifest antidepressant-like effects. Forced swim test (FST), tail suspension test (TST) and chronic unpredictable mild stress (CUMS) model of depression were explored to assess the antidepressant-like effect. Western blotting was further performed to detect the effects of PHC on the brain-derived neurotrophic factor (BDNF) signal cascade. Immunofluorescence was used to observe the activation of astrocyte. Moreover, different pharmacological inhibitors were applied to clarify the antidepressant-like mechanism. The results of the present experiments revealed that PHC decreased the immobility time of FST and TST in mice. In the CUMS model, PHC rapidly ameliorated anhedonia-like behavior (within 4 days), accompanying with the enhanced expression of BDNF and phosphorylation of extracellular signal-related kinase 1/2 (ERK1/2) in the hippocampus. In addition, blockade of the BDNF release by verapamil and activation of its Trk B receptor by K252a, rather than inhibition of opioid system by naloxone or sigma receptor by BD1047, abolished the antidepressant-like effects of PHC in mice. The findings suggest that PHC, an anti-muscarinic drug in clinical use, elicits rapid onset antidepressant-like effect, shedding light on the development of new antidepressants.
KeywordsPenehyclidine hydrochloride Muscarinic receptor Depression Antidepressant-like effect
This work was supported by fund from Xuzhou Medical University (2018kj05), and Priority Academic Program Development of Jiangsu Higher Education Institutes (PAPD).
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflict of interest.
- 1.Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, Owoeye O, Batten LA, Blier P (2019) Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry 176:401–409. https://doi.org/10.1176/appi.ajp.2018.18070834 CrossRefPubMedGoogle Scholar
- 4.Ghosal S, Bang E, Yue W, Hare BD, Lepack AE, Girgenti MJ, Duman RS (2018) Activity-dependent brain-derived neurotrophic factor release is required for the rapid antidepressant actions of scopolamine. Biol Psychiatry 83:29–37. https://doi.org/10.1016/j.biopsych.2017.06.017 CrossRefPubMedGoogle Scholar
- 10.Navarria A, Wohleb ES, Voleti B, Ota KT, Dutheil S, Lepack AE, Dwyer JM, Fuchikami M, Becker A, Drago F, Duman RS (2015) Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol Dis 82:254–261. https://doi.org/10.1016/j.nbd.2015.06.012 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R, Sanacora G, Eid T, Aghajanian G, Duman RS (2013) Scopolamine rapidly increases Mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 74:742–749. https://doi.org/10.1016/j.biopsych.2013.04.025 CrossRefPubMedGoogle Scholar
- 12.Lakstygal AM, Kolesnikova TO, Khatsko SL, Zabegalov KN, Volgin AD, Demin KA, Shevyrin VA, Wappler-Guzzetta EA, Kalueff AV (2019) DARK classics in chemical neuroscience: atropine, scopolamine, and other anticholinergic deliriant hallucinogens. ACS Chem Neurosci 10:2144–2159. https://doi.org/10.1021/acschemneuro.8b00615 CrossRefPubMedGoogle Scholar
- 23.Feng M, Wang L, Chang S, Yuan P (2018) Penehyclidine hydrochloride regulates mitochondrial dynamics and apoptosis through p38MAPK and JNK signal pathways and provides cardioprotection in rats with myocardial ischemia-reperfusion injury. Eur J Pharm Sci 121:243–250. https://doi.org/10.1016/j.ejps.2018.05.023 CrossRefPubMedGoogle Scholar
- 25.Wu X, Kong Q, Xia Z, Zhan L, Duan W, Song X (2019) Penehyclidine hydrochloride alleviates lipopolysaccharideinduced acute lung injury in rats: potential role of caveolin1 expression upregulation. Int J Mol Med 43:2064–2074. https://doi.org/10.3892/ijmm.2019.4117 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Saricicek A, Esterlis I, Maloney KH, Mineur YS, Ruf BM, Muralidharan A, Chen JI, Cosgrove KP, Kerestes R, Ghose S, Tamminga CA, Pittman B, Bois F, Tamagnan G, Seibyl J, Picciotto MR, Staley JK, Bhagwagar Z (2012) Persistent beta2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry 169:851–859. https://doi.org/10.1176/appi.ajp.2012.11101546 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J, Birnbaum J, Lyons DM, Rodriguez CI, Schatzberg AF (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 175:1205–1215. https://doi.org/10.1176/appi.ajp.2018.18020138 CrossRefPubMedPubMedCentralGoogle Scholar